Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Goldenberg

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Diabetes Technology & Therapeutics|July 16, 2020
The Canadian LMC Diabetes Registry: A Profile of the Demographics, Management, and Outcomes of Individuals with Type 1 DiabetesRonnie Aronson, Ruth E Brown, Alexander Abitbol, et al.
Diabetes Research and Clinical Practice|August 26, 2019
Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes studyRuth E Brown, Alexander Abitbol, Harpreet S Bajaj, et al.
Diabetes Research and Clinical Practice|September 6, 2020
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months resultsRonald Goldenberg, Alan Bell, Willoon Cheng, et al.
Journal of Cardiology|June 1, 2020
Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registryRonald Goldenberg, Alan Bell, Will Cheng, et al.
The New England Journal of Medicine|September 22, 2020
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin TreatmentJulio Rosenstock, Harpreet S Bajaj, Andrej Janež, et al.
Journal of Diabetes and Its Complications|August 4, 2019
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trialsRobert D Toto, Ronald Goldenberg, Glenn M Chertow, et al.
Clinical Immunology (Orlando, Fla.)|July 25, 2020
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteineHomam Ibrahim, Andras Perl, Deane Smith, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trialRonnie Aronson, Ruth E Brown, Lisa Chu, et al.
The Annals of Pharmacotherapy|September 21, 2018
Evaluation of Pharmacy-Developed Antibiotic Desensitization ProtocolsXian Jie Cindy Chen, Karen Fong, Diana Altshuler, et al.
Canadian Journal of Diabetes|March 23, 2023
Impact of the COVID-19 Pandemic on Antihyperglycemic Prescriptions for Adults With Type 2 Diabetes in Canada: A Cross-sectional StudyAlice Y Y Cheng, Ronald Goldenberg, Iris Krawchenko, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Diabetes Technology & Therapeutics|July 16, 2020
The Canadian LMC Diabetes Registry: A Profile of the Demographics, Management, and Outcomes of Individuals with Type 1 DiabetesRonnie Aronson, Ruth E Brown, Alexander Abitbol, et al.
Diabetes Research and Clinical Practice|August 26, 2019
Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes studyRuth E Brown, Alexander Abitbol, Harpreet S Bajaj, et al.
Diabetes Research and Clinical Practice|September 6, 2020
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months resultsRonald Goldenberg, Alan Bell, Willoon Cheng, et al.
Journal of Cardiology|June 1, 2020
Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registryRonald Goldenberg, Alan Bell, Will Cheng, et al.
The New England Journal of Medicine|September 22, 2020
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin TreatmentJulio Rosenstock, Harpreet S Bajaj, Andrej Janež, et al.
Journal of Diabetes and Its Complications|August 4, 2019
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trialsRobert D Toto, Ronald Goldenberg, Glenn M Chertow, et al.
Clinical Immunology (Orlando, Fla.)|July 25, 2020
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteineHomam Ibrahim, Andras Perl, Deane Smith, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trialRonnie Aronson, Ruth E Brown, Lisa Chu, et al.
The Annals of Pharmacotherapy|September 21, 2018
Evaluation of Pharmacy-Developed Antibiotic Desensitization ProtocolsXian Jie Cindy Chen, Karen Fong, Diana Altshuler, et al.
Canadian Journal of Diabetes|March 23, 2023
Impact of the COVID-19 Pandemic on Antihyperglycemic Prescriptions for Adults With Type 2 Diabetes in Canada: A Cross-sectional StudyAlice Y Y Cheng, Ronald Goldenberg, Iris Krawchenko, et al.
Pageof 5